As of May 2012 websites are required by law to gain your consent before applying cookies. We use cookies to improve your browsing experience. Parts of the website may not work as expected without them. By closing this message, you are consenting to our use of cookies. Close Learn more


Schizophrenia Package


> Download your free sample > Contact us to find out more



This comprehensive coverage provides up-to-date opinions and forecasts based on extensive secondary research backed by a survey of 140 high prescribing psychiatrists and detailed discussions with KOLs.  Learn how the disease is currently treated, the unmet needs and how new market entrants (branded and generics) will affect the market in the future.

The Datamonitor Healthcare difference

What this package includes

Total number of physicians interviewed

US Japan France Germany Italy Spain UK
Psychiatrists 32 24 19 16 15 17 17


Coverage summary


Reports included in package
  • Epidemiology
  • Marketed drugs profiles
  • Pipeline drugs profiles
  • Treatment (physician insights)
  • Patient-based drug forecasts
Countries evaluated US, Japan, France, Germany, Italy, Spain, UK
Patient-based drug forecast period 2012–21
Patient subpopulations forecasted
  • First line
  • Second line (and later)
Drugs profiled
  • Abilify
  • Abilify Maintena
  • Adasuve
  • Fanapt
  • Geodon
  • Invega/Invega Sustenna
  • Latuda
  • Risperdal/Risperdal Consta
  • Saphris
  • Seroquel
  • Zyprexa/Zyprexa Relprevv
  • Bitopertin
  • Brexpiprazole
  • Cariprazine
  • Pimavanserin
  • Zicronapine



Key Findings

The period 2011–12 saw an unprecedented number of blockbuster antipsychotics lose market exclusivity, most notably in the US with Zyprexa (olanzapine; Eli Lilly) in Q4 2011 and Seroquel (quetiapine; AstraZeneca) and Geodon (ziprasidone; Pfizer) in Q1 2012.

As the schizophrenia market stabilizes, with generic versions of atypical antipsychotics becoming the mainstay of treatment, companies involved must seek to innovate in order to deliver long-term success.

In the medium term, depot formulations of atypical antipsychotics promise to restore growth after a turbulent patent cliff, while the fate of drugs possessing novel modes of action, capable of augmenting traditional therapy, will govern the future direction of the schizophrenia market.

> Download your free sample > Contact us to find out more


Datamonitor Healthcare is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726